Neurimmune today announced that the company has appointed Dr. Natascha Schill Schulze to the newly created position VP Project and Alliance Management. At Neurimmune, Natascha Schill will be responsible for managing internal and external programs and alliances that are focused on the pharmaceutical development of novel therapeutic candidates for indications with high unmet medical need.
Natascha Schill, a biopharmaceutical executive, brings to Neurimmune more than 20 years of experience in regional and global roles in process development, commercialization, as well as program and alliance management. Prior to joining Neurimmune, Natascha Schill held various senior roles at Biogen and during her 22-years tenure at the company played an essential function in the development, launch and later commercialization of small and large molecule drugs and diagnostics that are today important for patients with multiple sclerosis. Since 2015, Natascha Schill was the Managing Director of Biogen Switzerland AG where she oversaw the commercial launch of three multiple sclerosis treatments and Biogen’s first treatment for spinal muscular atrophy.
“Neurimmune’s pipeline comprises a number of exciting new molecules for the treatment and prevention of neurodegeneration, cardiomyopathy, and metabolic disorders”, said Christoph Hock, co-founder and CMO of Neurimmune. “We are excited that Dr. Schill joins our company to implement and execute on our strategy to bring novel therapeutics to patients”.
Natascha Schill Schulze holds an M.S. in Biochemical Engineering from the Swiss Federal Institute of Technology in Zurich (ETH) and a Ph.D. in Biochemical Engineering from the Swiss Federal Institute of Technology in Lausanne (EPFL).
Contact Neurimmune
Fabian Buller, PhD
CBO
fabian.buller@neurimmune.com
Neurimmune AG
